Scarica l'app Stockscreener
3.27
3.25%
-0.11
Dopo l'orario di chiusura:
3.26
-0.01
-0.31%
Precedente Chiudi:
$3.38
Aprire:
$3.36
Volume 24 ore:
168.52K
Relative Volume:
0.67
Capitalizzazione di mercato:
$132.42M
Reddito:
-
Utile/perdita netta:
$-58.75M
Rapporto P/E:
-0.7557
EPS:
-4.327
Flusso di cassa netto:
$-50.79M
1 W Prestazione:
-8.15%
1M Prestazione:
-19.46%
6M Prestazione:
-7.63%
1 anno Prestazione:
+30.80%
Intervallo 1D:
$3.24
$3.42
Intervallo di 1 settimana:
$3.24
$3.90
Portata 52W:
$2.23
$5.38
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Nome
Onkure Therapeutics Inc
Settore
Industria
Telefono
(720) 307-2892
Indirizzo
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
3.27 | 136.88M | 0 | -58.75M | -50.79M | -4.327 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-30 | Iniziato | Evercore ISI | Outperform |
| 2024-12-05 | Iniziato | Leerink Partners | Outperform |
| 2024-10-10 | Iniziato | Oppenheimer | Outperform |
| 2023-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-12-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Iniziato | William Blair | Outperform |
| 2023-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2023-07-03 | Iniziato | BofA Securities | Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-27 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-22 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-05-04 | Iniziato | Jefferies | Buy |
| 2021-05-04 | Iniziato | Piper Sandler | Overweight |
| 2021-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Onkure Therapeutics Inc Borsa (OKUR) Ultime notizie
OnKure management will hold one-on-one investor meetings in New York - Stock Titan
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference - Yahoo Finance
OnKure (OKUR) Session: Ends Up by 0.25% at $3.94 in the Latest Reading; Key Range: Traders Can Monitor the $3.74-$4.14 Range in Latest TradingChannel Projection - vinanet.vn
Prosight Management, LP Reduces OnKure Therapeutics (OKUR) Stake in Second Quarter - GuruFocus
OnKure Therapeutics (OKUR): ADAR1 reports 5.5% stake as GP falls below 5% - Stock Titan
OnKure Therapeutics (OKUR) investor BVF discloses 8% stake plus 2.15M pre-funded warrants - Stock Titan
OnKure Therapeutics (OKUR) sees 3.6% passive stake reported by Trails Edge - Stock Titan
Oppenheimer Adjusts OnKure Therapeutics PT to $14 From $30, Maintains Outperform Rating - marketscreener.com
OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Points to Cost Discipline at Clinical-Stage BiotechEstimate Dispersion - vinanet.vn
OKUR Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 43.19%Revenue Recognition Risk - Vinanet
OnKure Reprices Underwater Stock Options to Boost Retention - TipRanks
Prosight entities report 2.4% OnKure Therapeutics (OKUR) stake in 13G/A - Stock Titan
OnKure Therapeutics (OKUR) Holds Steady at $4.14 as Biotech Consolidates Within Tight RangeEarnings Sentiment - dars.gov.et
Onkure Therapeutics Inc (OKUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
OnKure Therapeutics has cash runway into 2029 - BizWest
JonesTrading Maintains OnKure Therapeutics(OKUR.US) With Hold Rating - Moomoo
OnKure Therapeutics reports Q2 2026 net loss $15.3M; $176.4M cash runway into 2029 - TradingView
OKUR: IND-enabling PI3Ka programs advance toward 2027 filings, backed by $176M cash runway into 2029 - TradingView
OnKure Therapeutics, Inc. Q2 2026: Net loss $(30.5M) for 6M, EPS $(0.31) — 10-Q Summary - TradingView
OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - The Manila Times
OnKure Therapeutics (Nasdaq: OKUR) raises $150M to fund PI3Kα drugs - Stock Titan
OKUR: Q2 2026 net loss was $15.3M; cash reserves strengthened by $150M private placement - TradingView
OnKure Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OnKure Therapeutics Rings the Closing Bell - Nasdaq
OnKure Therapeutics Rings the Nasdaq Stock Market Closing Bell - Nasdaq
OnKure Therapeutics, Inc. Revenue Breakdown – NASDAQ:OKUR - TradingView
OnKure Therapeutics (OKUR) Falls 4.5% to $3.82: Support at $3.63 Faces Key TestLast Point Support - vinanet.vn
Vivo Capital LLC Invests $7.98 Million in OnKure Therapeutics, Inc. $OKUR - MarketBeat
Onkure Therapeutics Inc (OKUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Onkure Therapeutics Inc (OKUR) Balance Sheet - TradingKey
Onkure Therapeutics Inc (OKUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKUR|Onkure Therapeutics Inc|Price:4.050|Chg%:-0.070 - TradingKey
Onkure Therapeutics Inc (OKUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OnKure Therapeutics (OKUR) Slips 1.7% as Shares Test Key Support ZoneEMA Signal - vinanet.vn
Onkure Therapeutics Inc (OKUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Institutional Confidence - TradingKey
Onkure Therapeutics Inc (OKUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Onkure Therapeutics Inc (OKUR) Cash Flow - TradingKey
Onkure Therapeutics Inc (OKUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKUR Q1 2026 Earnings: Wider-than-expected loss as clinical-stage biotech progresses pipelineBanking Earnings Report - vinanet.vn
Onkure Therapeutics Inc (OKUR) Income Statement - TradingKey
OKUR Options Volatility — NASDAQ:OKUR - TradingView
OKUR Options Chain — NASDAQ:OKUR - TradingView
Price to earnings forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
OnKure Therapeutics (OKUR) Rises 3.6% as Stock Approaches Key Resistance LevelBPI Bear Correction - vinanet.vn
Price to sales forward of OnKure Therapeutics, Inc. – NASDAQ:OKUR - TradingView
H.C. Wainwright cuts OnKure stock price target to $21 on valuation changes - Investing.com
OKUR Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
OnKure Therapeutics Price Target Cut to $21.00/Share From $27.00 by HC Wainwright & Co. - Moomoo
H.C. Wainwright Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $21 - Moomoo
Onkure Therapeutics Inc Azioni (OKUR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):